Halozyme Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Halozyme Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Halozyme Therapeutics Inc.
Rating: 2.081277625
Author: Trendlyne DVM scores

Mid-range Performer

about

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary ...

63.06 -0.80 (-1.25%)

32.76% Gain from 52W Low

1.2M

XNAS Volume

XNAS 29 Apr, 2026 5:30 PM (EDT)

Board Meeting

The next board meeting for Halozyme Therapeutics Inc is on 06 May 2026 for the purpose of Halozyme Therapeutics Inc First Quarter Earnings Results for 2026 See details

Medium Financial Strength

44.4 / 100

Mid Valuation

42.3 / 100

Technically Neutral

35.3 / 100

Mid-range Performer These stocks have average quality, financial and technical momentum, indicating a mid range performer View Similar Embed DVM

1Yr Price target upside is 36%

9 analysts

Halozyme Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Halozyme Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary ...

32.76% Gain from 52W Low

SWOT Analysis

Halozyme Therapeutics Inc Live Price Chart